ALS Drug Access Debated

The Scientist - 2 weeks ago
In addition to the Phase 2...

Gov. Deal signs bill allowing use of cannabis oil

Atlanta Business Chronicle - 3 days ago
As it went through the legislature...

Dead on: Powerful overdose antidote plan wins some local support

Bradford Era - 5 days ago
They include Advanced Life Support...

Feature: How tiny satellites spawned in Silicon Valley will monitor a changing ...

Science /AAAS - 1 week ago
The boundaries of pit mines...

Villanova's NCAA Final victory over Georgetown shook the sport and ...

SI.com - 3 weeks ago
What follows is an expanded and...

LA-RICS looks to state, feds for help to salvage public-safety LTE project

Urgent Communications - 2 weeks ago
Recent actions by the Los Angeles...

Feature Story: 2015 Economic Development Awards

Business Facilities Magazine (press release) (blog) - 2 weeks ago
Brown brought together business...

Florida Tries Again on Medical Marijuana

WCTV - 3 weeks ago
The new list includes HIV,...

Summary: A Safe And Secure Iowa Medical Cannabis Program

Blog for Iowa (blog) - 3 weeks ago
Iowans strongly believe that their...

Reflecting on 35 Years of Innovation in JEMS

JEMS.com - 3 weeks ago
Our visionary, specially focused...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.